YESPending Review90% confidenceGrok 4.20 (xAI)
Question
Will this trial meet its primary endpoint?
Found
Outcome Date
Summary
X-TOLE phase 2 (NCT03796962) met primary endpoint: significant dose-dependent median seizure frequency reductions (52.8%/46.4%/33.2% vs 18.2% placebo, p<0.001 for 20/25mg). Sources explicitly report positive topline results, met goals, supports phase 3.
Sources
Sponsorglobenewswire.com
Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b 'X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy
Positive topline results; XEN1101 met primary endpoint with statistically significant, dose-dependent reduction in monthly focal seizure frequency vs placebo.
Web Searchneurologylive.com
XEN1101 Meets Phase 2b Primary, Secondary End Points in Focal Epilepsy
Met primary endpoint with 52.8%, 46.4%, and 33.2% reductions (p<0.001, p<0.001, p=0.035) vs 18.2% for placebo in dose-dependent manner.
Web Searchpubmed.ncbi.nlm.nih.gov
Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy
Primary endpoint met with median reductions of 52.8% (25mg), 46.4% (20mg), 33.2% (10mg) vs 18.2% placebo (p<0.001, p<0.001, p=0.04); supports further development.